EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. - Wikidata - wikimedia - TriplyDB

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

http://www.wikidata.org/entity/Q36285345

about

Emerging blood-based biomarkers for detection of gastric cancer Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study Lung Cancer Gene Signatures and Clinical Perspectives Development and validation of a high throughput system for discovery of antigens for autoantibody detection Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies.Peptides from the variable region of specific antibodies are shared among lung cancer patients.Assessment of the cancer risk factors of solitary pulmonary nodules A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.Serum autoantibody measurement for the detection of hepatocellular carcinoma Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.Potential biomarkers for lung cancer screening Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer Progress in the development of volatile exhaled breath signatures of lung cancer.Circulating antibodies to p16 protein-derived peptides in breast cancer Human Blood Autoantibodies in the Detection of Colorectal Cancer.Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.Triple-layer dissection of the lung adenocarcinoma transcriptome: regulation at the gene, transcript, and exon levels Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer.Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts.Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma Diagnostic Value of Autoantibodies against Ezrin in Esophageal Squamous Cell Carcinoma Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.Systematic review: serum autoantibodies in the early detection of gastric cancer.Current status of circulating protein biomarkers to aid the early detection of lung cancer.Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers.The challenge of small lung nodules identified in CT screening: can biomarkers assist diagnosis?Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines.Biomarkers along the continuum of care in lung cancer.The biomarker landscape in mycosis fungoides and Sézary syndrome.Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer.BARD1 serum autoantibodies for the detection of lung cancer.

P2860

Q26778026-61FF9C33-C573-4EF7-B819-E3616DD2B219 Q27348798-82E7E488-B5B1-4EFF-84CC-282C8F78BB6F Q28387769-29510B8F-56D7-4747-85A4-608A6522E461 Q28729058-44E6643D-EEE2-47BF-892B-82514F373C87 Q31126986-4AC70277-0B4C-48CC-AD17-4EF8DAD82B7A Q33553735-82C83DE5-F389-461B-A896-734DD44446F5 Q33710108-DC4744A4-68A8-4E1F-B596-D77AB3A0BAD6 Q33968948-1C6AA908-19A9-427B-8387-738E125B9104 Q34004797-242ED2C3-F9F2-489F-AACC-58DF7FE60C8A Q34049184-D1238DFF-2548-4301-AB3A-935566DC787E Q34525089-34FF4D4E-1629-4A6B-A7D8-E212D220890F Q35104929-9870356B-6806-4AD5-B928-E13005830A62 Q35200580-09C574A3-4C5A-4BA9-A987-27D1D9980801 Q35244082-6BB7AA6E-6057-4A2E-B3FA-3397D63B2D86 Q35565146-B7D6643A-F7D2-4AD8-93A4-63B44EB72E0C Q35753707-501992C8-A536-483C-9C72-5256DE23B724 Q36068902-EB3EDBD5-2B81-43D9-9A66-DB7871222E67 Q36146042-C9DC1358-24D0-4E0E-8B9B-D37EABCDA055 Q36305136-40A88345-8F76-4816-8D2F-E5F91E2ED96D Q36557126-63C2D9C3-1A4C-4F50-8297-DEA064078480 Q36860418-2A257059-5CC6-4341-9DFC-39E26033AE6C Q36896106-322962D2-9EEB-4841-B0FF-089B1ED32384 Q37086048-00C80050-D70D-48DA-8472-21F5A108E7BC Q37094902-119A6AD3-C51E-4EFD-AA68-2DF83B95EEC5 Q37274622-F9A42A34-9D14-483E-82EE-69BABC71E188 Q37549330-0BDA6597-3674-429A-A4D4-CA7D7C933130 Q37580040-7831FAA4-DFEC-43B3-B7DB-EC93EEBE27E7 Q37621102-D62E51EC-2945-4C63-B288-FD673655C468 Q37681008-F700BB6F-09E7-4BAB-83A6-B85B794142E4 Q37721848-63124F98-5962-4B74-8D07-208ACEADDAAA Q38172914-92DCEDA3-1BD8-42AF-8748-44111508DF96 Q38194925-2E3CB222-6461-453E-B76F-03A93AD41EEF Q38232856-865835A3-D80D-4F9E-9387-83E5B8BF26D0 Q38238438-954B173A-715D-439E-9AD6-EF76871BFD49 Q38695926-BC81F572-2F65-4BE1-868C-87D85F721D08 Q38718638-9CEB5459-5C21-42F4-AD77-EE346A370DB8 Q38829721-2AD4FEFD-A237-4D57-9DE3-F16CDF43C6F4 Q39023382-960DAC3D-59A6-49CC-8DAB-EB6E6FF228A4 Q41144323-188CF69B-E1A5-4AE6-80A8-C5A9EF30AD8A Q41281453-122BC2BC-C641-4BBA-B620-FE2F3D150E94

P2860

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

http://www.wikidata.org/entity/Q36285345

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@ast

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@en

type

label

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@ast

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@en

prefLabel

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@ast

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@en

P1433

Q36285345-E1D3D878-3450-4B18-9B6B-ED0D01CCFE0F

P1476

Q36285345-64F9B63A-5FCB-432A-AC99-5BD1DEBE8BF5

P2093

Q36285345-12108433-B899-4829-897A-E5D80854277E

Q36285345-269A704D-B93D-4B28-B2A2-4A0FDDA363CA

Q36285345-3924D1B5-3CF6-44D9-8184-AFD28BA824AD

Q36285345-41ED0391-D0FB-4474-9E74-C23C1999D6B1

Q36285345-45AD4298-C6E6-4430-9EE3-284FC2595683

Q36285345-7C15B323-B1A9-403D-AB9D-1C6C2E85554D

Q36285345-8B504D14-247B-468E-B01A-F401AB5C3905

Q36285345-9A59839C-38EA-455A-B383-CDA378DBB2D9

Q36285345-9A6C2F9F-ECC5-482B-BBA2-4A94B48804FB

Q36285345-A33387D8-F38C-4F5A-A7B1-72A3D06D5E74

P2860

Q36285345-0A8EEB66-EDBB-4FDB-85FD-9649B5952775

Q36285345-0B7DE4C2-36D2-474B-BEC3-38471A5BE2B6

Q36285345-15EFB997-5BBE-4EEC-A19C-9791A3864FD3

Q36285345-23A50594-4D6F-4B00-B8CA-AD611FF8A6C1

Q36285345-28C7ED3E-60BC-4D1A-A53C-58023904CE25

Q36285345-2AE49E55-AC32-4B81-A9F6-3597CF5C290B

Q36285345-2B6FA927-243D-4520-AB2F-3F545A9CF352

Q36285345-381E075A-BF28-46F7-AE0C-F0ED27FC2309

Q36285345-41E710C6-8F44-4D3E-A9E2-A9A1776C0F82

Q36285345-4770060E-1426-4670-BC3A-AB7A76703EF3

P2888

Q36285345-B2B1F084-7D4C-4EA7-9049-BFB4B15A80B4

P304

Q36285345-1208252C-F11B-44B5-B76B-41E19625BC0E

P31

Q36285345-D1BD36E4-D794-4EC3-91D0-57FC79BECD4E

P356

Q36285345-6FF799E9-FFDC-4F58-A36A-496D294BC15B

P433

Q36285345-F1530051-4ED5-489F-9C01-C6FA686167E4

P478

Q36285345-76BE318E-3681-423E-A625-16B9379DDD71

P50

Q36285345-0D648F78-512B-4580-B7C5-9BD8E083BC3E

Q36285345-A982F421-4411-46C1-9D24-B1D0350B5AD8

P577

Q36285345-1240C9FB-8E5A-4E2D-AE8A-62DFD0C0EACF

P5875

Q36285345-ECD474F1-9549-47B1-84C4-D9A9EFEEF1A1

P698

Q36285345-816AAFAE-0ED3-4763-BCBF-33869C75BB9F

P921

Q36285345-A17C9A9E-88CB-4E03-99E0-3ED468560621

P932

Q36285345-C50F8566-2A1F-49EF-A73D-C7F410EED8A4

P356

S13277-012-0379-2

P1433

P1476

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

@en

P2093

Alison J Thorpe

http://www.w3.org/2001/XMLSchema#string

Andrea Murray

http://www.w3.org/2001/XMLSchema#string

Caroline J Chapman

http://www.w3.org/2001/XMLSchema#string

Celine B Parsy-Kowalska

http://www.w3.org/2001/XMLSchema#string

Chris Robertson

http://www.w3.org/2001/XMLSchema#string

Geoffrey Hamilton-Fairley

http://www.w3.org/2001/XMLSchema#string

Graham F Healey

http://www.w3.org/2001/XMLSchema#string

Isabel K MacDonald

http://www.w3.org/2001/XMLSchema#string

John F R Robertson

http://www.w3.org/2001/XMLSchema#string

Laura J Peek

http://www.w3.org/2001/XMLSchema#string

P2860

Role of HuD and other RNA-binding proteins in neural development and plasticity

Reduced lung-cancer mortality with low-dose computed tomographic screening

Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance

Profiling tumor-associated antibodies for early detection of non-small cell lung cancer.

The RNA-binding protein HuD regulates neuronal cell identity and maturation.

Technical validation of an autoantibody test for lung cancer.

Early lung cancer action project: a summary of the findings on baseline screening.

Clinical validation of an autoantibody test for lung cancer.

CT screening for lung cancer: five-year prospective experience.

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

P2888

s13277-012-0379-2

P304

1319-1326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-012-0379-2

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223973665

http://www.w3.org/2001/XMLSchema#string

P698

22492236

http://www.w3.org/2001/XMLSchema#string

P921

P932

3460172

http://www.w3.org/2001/XMLSchema#string